# Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

> **NCT01194193** · PHASE1 · WITHDRAWN · sponsor: **AstraZeneca** · enrollment: 63 (estimated)

## Conditions studied

- Cancer
- Advanced Solid Tumours
- Lymphomas

## Interventions

- **DRUG:** AZD8055

## Key facts

- **NCT ID:** NCT01194193
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 63 (ESTIMATED)
- **Why stopped:** Amendment to study compound development programme
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194193, "Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01194193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*